Related references
Note: Only part of the references are listed.Relationship Among Gefitinib Exposure, Polymorphisms of Its Metabolizing Enzymes and Transporters, and Side Effects in Japanese Patients With Non-Small-Cell Lung Cancer
Hiroyuki Kobayashi et al.
CLINICAL LUNG CANCER (2015)
Impact of single nucleotide polymorphisms on severe hepatotoxicity induced by EGFR tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring EGFR mutations
Eri Sugiyama et al.
LUNG CANCER (2015)
Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer
Masayuki Takeda et al.
LUNG CANCER (2015)
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
Yi-Long Wu et al.
LANCET ONCOLOGY (2014)
Polymorphisms of CYP2D6 Gene and Gefitinib-Induced Hepatotoxicity
Takayuki Takimoto et al.
CLINICAL LUNG CANCER (2013)
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
Lecia V. Sequist et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Appropriate Chemotherapy Dosing for Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline
Jennifer J. Griggs et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Rafael Rosell et al.
LANCET ONCOLOGY (2012)
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
Caicun Zhou et al.
LANCET ONCOLOGY (2011)
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
Tetsuya Mitsudomi et al.
LANCET ONCOLOGY (2010)
Association between poor performance status and risk for toxicity during erlotinib monotherapy in Japanese patients with non-small cell lung cancer: Okayama Lung Cancer Study Group experience
Katsuyuki Hotta et al.
LUNG CANCER (2010)
Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR.
Makoto Maemondo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes
Jing Li et al.
CLINICAL CANCER RESEARCH (2007)
Being overweight influences the development of hepatic dysfunction in Japanese patients with non-small-cell lung cancer undergoing cytotoxic chemotherapy
Yoshiro Fujiwara et al.
LUNG CANCER (2007)
Hepatic CYP3A expression is attenuated in obese mice fed a high-fat diet
Kouichi Yoshinari et al.
PHARMACEUTICAL RESEARCH (2006)
High initial blood levels of tacrolimus in overweight renal transplant recipients
E Rodrigo et al.
TRANSPLANTATION PROCEEDINGS (2005)
Randomized pharmacokinetic and pharmacodynamic study of docetaxel: Dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol
N Yamamoto et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol
HC Swaisland et al.
CLINICAL PHARMACOKINETICS (2005)
Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies
C Barba et al.
LANCET (2004)
Factors affecting the pharmacokinetics of CPT-11: The body mass index, age and sex are independent predictors of pharmacokinetic parameters of CPT-11
T Miya et al.
INVESTIGATIONAL NEW DRUGS (2001)
The benefits of chemotherapy in patient subgroups with unresectable non-small-cell lung cancer
LJ Billingham et al.
ANNALS OF ONCOLOGY (2001)
Effects of obesity on pharmacokinetics - Implications for drug therapy
G Cheymol
CLINICAL PHARMACOKINETICS (2000)
Share Paper
